This last designation is in contrast to the WHO, which still requires blast counts of at least 20% for a diagnosis of acute myeloid leukemia (AML) in the absence of certain specific AML-defining genetic abnormalities (e.g., PML::RARA fusion, RUNX1::RUNX1T1 fusion, etc). The gene discussed is RARA; the disease is acute myeloid leukemia.